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• Implementation of Lynch syndrome screening in endometrial cancer can be improved.
• Gynaecologists ought to be aware of Lynch syndrome screening in endometrial cancer and might require additional training.
• Quality assurance protocols should be implemented to ensure adherence to Lynch syndrome screening in endometrial cancer.Abbreviations: IHC, immunohistochemistry; LS, Lynch
cient; MSI, microsatellite instability.
⁎ Corresponding author at: MC Cancer Institute, Univer
E-mail address: alberttjalsma@gmail.com (A.S. Tjalsma
https://doi.org/10.1016/j.ygyno.2020.12.028
0090-8258/© 2020 The Authors. Published by Elsevier Inc
Please cite this article as: A.S. Tjalsma, A.Wag
patients with endometrial can..., Gynecologica b s t r a c ta r t i c l e i n f oArticle history:
Received 24 September 2020
Accepted 21 December 2020
Available online xxxxObjective. In the Netherlands a nationwide guideline was introduced in 2016, which recommended routine
Lynch syndrome screening (LSS) for all women with endometrial cancer (EC) <70 years of age. LSS consists of
immunohistochemical (IHC) staining for loss of mismatch repair (MMR) protein expression, supplemented
withMLH1methylation analysis if indicated. Test results are evaluated by the treating gynaecologist, who refers
eligible patients to a clinical geneticist. We evaluated the implementation of this guideline.
Methods. From the nation-wide pathology database we selected all women diagnosed with EC < 70 years of
age, treated from 1.6.2016–1.6.2017 in 14 hospitals.We collected data on the results of LSS and followup of cases
with suspected LS.
Results. In 183 out of 204 tumours (90%) LSS was performed. In 41 cases (22%) MMR protein expression was
lost, in 25 cases due to hypermethylation of theMLH1 promotor. One patientwas knownwith a pathogenicMLH1
variant. The option of genetic counsellingwas discussedwith 12 of the 15 remaining patients, of whom three de-
clined. After counselling by the genetic counsellor nine patients underwent germline testing. In two nosyndrome; LLS, Lynch-like syndrome; LSS, Lynch syndrome screening; MMR, mismatch repair; MMRd, mismatch repair defi-
sity Medical Centre Rotterdam, Dr. Molewaterplein 40, PO BOX 2040, 3000, CA, Rotterdam, the Netherlands.
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A.S. Tjalsma, A. Wagner, W.N.M. Dinjens et al. Gynecologic Oncology xxx (2021) xxxpathogenic germline variant was detected, two were diagnosed with a pathogenic PMS2 variant, and five with a
pathogenicMSH6 variant, in concordance with the IHC profiles.
Conclusion. Coverage of LSS was high (90%), though referral for genetic counselling could be improved.
Gynaecologists ought to be aware of the benefits and possible drawbacks of knowing mutational status, and re-
quire training in discussing this with their patients.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Endometrial cancer is the most common gynaecological malignancy
in the Netherlands [1].and in other high income countries [2,3]. It is the
second most common gynaecological cancer worldwide [4], and in re-
cent years there has been an increase in the incidence of endometrial
cancer globally [3]. Risk factors for endometrial cancer are nulliparity,
late onset ofmenopause, prolonged oestrogen exposure, obesity and ta-
moxifen use. There are also genetic predispositions for endometrial car-
cinoma recognised, as is the case in Lynch syndrome (LS). LS is
characterized by early onset of colorectal carcinoma, endometrial carci-
noma and other extra colonic cancers [5,6]. A gynaecological malig-
nancy will be the first presentation in more than 50% of women with
LS, and 6% of cases of EC ˂ 70 are caused by LS [7]. LS is an autosomal
dominant condition caused by germline pathogenic variants in DNA
mismatch repair (MMR) genes (MLH1, MSH2, MSH6, PMS2) and
TACSTD1 [8] or more rare constitutional epimutation in the promotor
regions of MLH1 or MSH2 [9]. Complete inactivation of one of the
MMR proteins, as the result of pathogenic mutations in a MMR gene
or hypermethylation of theMLH1 promotor, causes instability in highly
repetitiveDNA sequences, known asmicrosatellite instability (MSI). Im-
munohistochemistry (IHC) for MMR proteins and MSI analysis can be
used to detect loss of MMR function. Since sporadic MMR deficient
(MMRd) tumours can be due to hypermethylation of the MLH1
promotor in the tumour, in the case of absentMLH1 protein expression,
MLH1 hypermethylation analysis is carried out to distinguish between
sporadic MLH1 deficient tumours and tumours likely to be caused by
LS [10,11]. To confirm or exclude the presence of an underlying
germline variant referral for genetic testing is indicated for patients sus-
pect of LS. If germline testing does not reveal a pathogenic germline var-
iant, these patients may have a Lynch-like syndrome (LLS). Partially
these patients could have an undetected pathogenic germline variant,
though studies have demonstrated that in colorectal cancer up to 69%
of such nongermline MMR-deficient cases may be due to somatic
events. [12–15] Although LLS patients have a lower risk of developing
CRC compared to LS patients, their risk is higher than patients with spo-
radic CRC [16].
Identification of subjects carrying a pathogenic MMR gene variant is
important, because surveillance colonoscopy in these people is associ-
ated with improved overall and colorectal cancer related mortality
[17]. For the detection of LS in patients with endometrial cancer, current
guidelines and policies show a broad spectrum concerning the age and
criteria to commence tumour screening [18,19,20]. Routine tumour
screening for LS (LSS) for women with EC <70 years of age has shown
to be cost effective, allowing them and their relatives to benefit from
surveillance colonoscopy [21]. Since January 2016 this strategy is incor-
porated into the Dutch national guideline concerning endometrial can-
cer. This guideline is developed by the Guideline Commission
Gynaecologic Oncology (RCGO) and published by theNetherlands Com-
prehensive Cancer Organization (IKNL) [22]. The guideline recom-
mends LSS by IHC because this can be implemented easily in all
pathology laboratories and is most cost effective; MSI analysis is only
advised in case of inconclusive IHC results [23]. The primary outcome
of this study was to record to what extent the current Dutch national
guideline was implemented in daily practice; whether patients under
the age of 70 years with an endometrial carcinoma were screened for2
LS, and whether eligible patients were referred to a clinical geneticist.
The secondary outcomes were the technique used to screen for LS
(IHC or MSI analysis), the specimen on which the screening was per-
formed (endometrial biopsy or hysterectomy specimen) and the final
diagnosis of a germline pathogenic variant.
2. Methods
Via the Dutch Pathology Registry (PALGA; Nationwide network and
registry of histopathology and cytopathology in the Netherlands
encompassing all histology reports in the Netherlands since 1974) a
search was performed to identify all patients with endometrial carci-
noma younger than 70 years within two regional oncology networks
in the Southwest Netherlands encompassing 14 hospitals, listed in the
acknowledgments. Cases from the period July 2016 to July 2017 were
included. Patients with a different diagnosis, those that were treated
outside the catchment area, or before or after the inclusion period
were excluded. A database was compiled containing the anonymous
data for the included cases. These data were then analysed for tumour
characteristics and MMRd analysis.
After identifying patients with loss of expression of a MMR protein,
we assessed whether MLH1 hypermethylation analysis was performed
if indicated. The hypermethylation analysis was always performed on
both the tumour and normal tissue to exclude constitutional
epimutations. Once the remaining patients at risk of LS were identified,
the gynaecologist who treated the patient was contacted through the
PALGA portal. This portal ensured anonymity of the patients but made
it not possible to extract data from the patient file personally. The clini-
cian was asked i) whether the patient was informed about the findings,
ii) if the patient was referred to a clinical geneticist, iii) if the patient
went for counselling and iv) the outcome of genetic tests. These data
were included in the database and implementation of the guideline
was evaluated.
Statistical analyses were performed using SPSS, version 25.0.0.1
(SPSS Inc., Chicago, IL, USA). This study was approved by the Medical
Ethical Commission of the Erasmus MC Cancer Institute (MEC-2018-
1292) and all participating hospitals.
3. Results
3.1. Screening for LS
A total of 238 reports coded with a diagnosis of endometrial carci-
noma were collected from the PALGA database. After assessment of
the reports 34 cases were excluded due to treatment in another region
or another diagnosis, leaving 204 cases with endometrial carcinoma. In
21 cases (10%) IHC or MSI analysis was not performed. Follow up of
these patients who were not screened revealed a variety of reasons. In
some cases it was not yet standard protocol to perform LSS in the pa-
thology laboratory and the screening was not specifically requested by
the treating gynaecologist.
After this study had revealed that the information was missing,
screening was performed later for two patients. Both cases ap-
peared to have an increased risk for LS, unfortunately one
woman died before the screening result became available. The
other patient was referred for genetic counselling and germline
A.S. Tjalsma, A. Wagner, W.N.M. Dinjens et al. Gynecologic Oncology xxx (2021) xxxtesting, which identified a pathogenic MSH6 variant. These patients
were not included in the further analyses concerning implementa-
tion of the guideline.
The clinicopathologic features of all LS screened cases are shown in
Table 1. The vast majority of cases showed endometrioid histology
(155/183, 85%). Eleven patients showed metastasis in the ovaries. Con-
comitant epithelial ovarian cancer was not reported. Two patients had a
concurrent second tumour; one patient had a granulosa cell tumour in
the ovary and one patient an oesophageal carcinoma (T2,N0). MMR
analysis was performed by IHC in the majority of cases (180/183), in
three cases MSI analyses was carried out, and in two cases both IHC as
MSI analyses was conducted. The MMR analyses showed loss of MMR
protein expression on immunohistochemistry in 41 cases (22%), subse-
quent testing showed tumour-specific hypermethylation of the MLH1
promotor in 25 cases (14%) and these tumours were considered to be
sporadic tumours. The remaining 16 cases (9%), loss of MLH1 in 5
cases, loss of PMS2 in 5 cases and loss of MSH 6 in 6 cases, were consid-
ered at risk of a pathogenic MMR gene germline variant. One patient
was already known to have a pathogenic germline MLH1 variant, she
was not referred to a clinical geneticist. (Fig. 1).
3.2. Referral and germline testing
There were 15 patients at risk of an as yet undiagnosed germline LS
pathogenic variant. Three patients were not informed about the tissue
screening result and were not referred to a clinical geneticist. We
could not establish the reason why the screening results were not
discussed with these patients. Twelve patients were advised to consult
a clinical geneticist, of whom three declined referral. One patient
refrained from genetic counselling because her husband was terminally
ill, she also withdrew from gynaecological follow up. The clinical files
did not elucidate why the other two patients declined genetic counsel-
ling. The remaining nine patients visited the clinical geneticist and
underwent germline testing; in two no pathogenic germline variant
was detected, two were diagnosed with a pathogenic PMS2 variant
and five with a pathogenic MSH6 variant.Table 1
histopathological characteristics of screened patients.
MMRp (n) % MLH1/PMS2 loss and hypermethy
142 77 25





Endometrioid 117 82 24
Grade 1 89 10
Grade 2 15 11
Grade 3 12 3
Unknown 1
Serous 13 9 0
Clear cell 4 3 0
Carcinosarcoma 6 4 0
Undifferentiated 0 0 1
Mixed type 1 1 0
Uncertain diagnosis 1 1
Stage
T1a 73 51 17
T1b 38 27 5
T2 6 4
T3a 7 5 2
T3b 2 1
T4 1 1






The primary outcome of our study was to evaluate whether the
guideline concerning screening for LS in women with endometrial can-
cerwas being implemented. Over 90% of patientswith endometrial can-
cer underwent screening for LS, which is in accordance with the recent
results of Lentz et al. [24] This study reports the implementation of two
different strategies concerning LSS. In the region where reflex testing
was implemented there was a screening rate of 84%. Despite the fairly
good coverage of LSS in our study, 100% ought to be the aim. Two
women in our study who were initially not screened but were tested
in hindsight, were both at increased risk of LS with one of them actually
having a germline pathogenic variant. Due to this diagnosis cascade
testing of family members can be performed and carriers can benefit
from surveillance colposcopy and gynaecological follow up. The other
patient died prior to the test outcome, causing difficult ethical issues
since relatives may be at risk, which could have been avoided with
timely screening. Lentz et al. argued that most of the patients without
IHC results in their study were from the initial period of the screening
program. Based on the replies from the laboratories why screening
was not performed, this could also be the case in our study. Also lack
of awareness of guidelines concerning LSS has previously been demon-
strated among pathologists [25]. In the current standardized national
synoptic pathology report [26] the completion of MMR immunohisto-
chemical testing results is included, ensuring that IHC for MMR will be
performed. Widespread use of this national reporting protocol should
help push screening towards the necessary 100%.
Screening was performed in 30% of cases on the diagnostic sample.
Research has demonstrated that screening for LS on such samples is
just as accurate as screening on hysterectomy specimens [27]. In 6% of
cases LSS was performed on both specimens, underlining the need for
local protocols and quality assessment to prevent wasting resources.
Whether LSS is performed on the biopsy or the hysterectomy specimen,
it must be clear at what stage the counselling of the patient should be
performed, and by whom. In five cases MSI analyses was performed of
which two cases it was combined with IHC. The reason why MSI waslated promotor (n) % MMRd (n) % Total (n) %










0 0 13 7
0 0 4 2
1 5,6 7 4
4 0 0 1 0,5
1 5,6 2 1
0 0 1 0,5
68 13 82 103 56
20 0 0 43 24
2 11 8 4
8 0 0 9 5
0 0 2 1
0 0 1 0,5
4 1 11 17 9,5
12 75 12 7
9 56 9 5
7 44 7 4
Fig. 1. Nationwide Dutch guideline for detecting Lynch syndrome (LS) in women with endometrial cancer < 70 years of age.
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result of IHC after which MSI analysis demonstrated that the tumour
was microsatellite stable. To ensure uniformity in the execution of the
guideline, it is advisable that laboratories initiate screening by IHC and
only use MSI analysis in case of an inconclusive IHC result.
Of the screened patients, 8% (15/183) were at increased risk of an as
yet undiagnosed LS, however 20% of these patients were not informed
about this finding. This is in contrast to the AMA Code ofMedical Ethics,
in which the right to know is explicitly spelled out. Patients should have
been informed about their test results, especially since the result of
germline testing can have amajor impact on the future health of the pa-
tient and her familymembers.We could not establish why these results
were not shared with the patient. Several issues might be relevant: ig-
norance of the result, a knowledge gap (the gynaecologist does not un-
derstand the IHC test results) and unease with genetic counselling have
all been reported previously [28,29].
In the Netherlands a standardized format is used for the reporting of
IHC test results, including advice on additional testing andwhen referral
to a geneticist is indicated. This standardized reporting should ensure
that gynaecologists know what action ought to be taken. It could be ar-
gued that universal endometrial cancer screening for LS would increase
the uptake of LSS. It would increase awareness of both pathologists and
gynaecologists, that a test result is required for optimal patient care.
There is no international consensus up to what age and under which
criteria routine diagnostics for heritable causes of MMR deficiency is in-
dicated. [18,19,20,23] Due to the fact that LSS has been shown cost effec-
tive in patients with EC < 70 years, till now the Dutch guideline has
limited the screening up to 70 years of age. Introducing a monitoring
system, to check that IHC test results have been communicated to all pa-
tients, can prevent that patients are unaware of their LS risk.
Weperformed a short survey on knowledge about LS, and familiarity
with the current guideline, among gynaecologists and residents visiting
a regional meeting where the preliminary results of this study were4
presented (September 2018). See Supplementary Table 1 for the ques-
tions asked and the results. This survey revealed a lack of knowledge
concerning the indication for LSS. Less than 50% of the respondents an-
swered these questions correctly, the result was worse for
gynaecologists than for junior residents. This urges the need for educa-
tion of gynaecologists regarding LS.
Seventy-five percent of those patients counselled about genetic test-
ing by the gynaecologist agreed to be referred to the clinical geneticist
and all referred patients underwent germline analysis. Previous studies
reporting on genetic counselling for LS endometrial carcinoma patients
have shown variable percentages for referral to a clinical geneticist:
ranging from 44 to 94%. [30–36] This fairly high acceptance rate for ge-
netic counselling could be due to the organization of our health care sys-
tem. It has been demonstrated that the lack of insurance coverage was
one of the major reasons to decline germline testing. [30] The availabil-
ity of accessible services and the cost structure of genetic counselling
and testing within the Dutch health care system lower the barriers for
patients to accept genetic counselling. For two of the three patients
who refused referral the reason was unclear, and we are unable to de-
termine whether these patients might have been willing to be referred
later. Though genetic counselling services are embedded within our
health care system, patientsmay still perceive several barriers to partic-
ipation [29]. First of all, some patientsmay not see the benefit of genetic
counselling for themselves or their siblings. This could change if the
presence of a pathogenic germline variant is shown to lead to adjuvant
treatment options. Also patients have reported that there was a paucity
of informationwhen they were informed about the genetic counselling,
and this limited information may be a reason why they do not partici-
pate. This could be due to lack of knowledge and urges the need for ed-
ucation and training of gynaecologists also regarding genetic
counselling in case of aberrant MSI results e.g. by e-learning. It has
been demonstrated that e-learning can be an effective method for en-
hancing counselling skills [37]. Thirdly, the timing of the counselling
A.S. Tjalsma, A. Wagner, W.N.M. Dinjens et al. Gynecologic Oncology xxx (2021) xxxby the gynaecologist could be important for patients considering refer-
ral to the clinical geneticist. Patientsmight experience an overload of in-
formation at the time of diagnosis, andmay be less receptive for referral
to a clinical geneticist [29]. However, in patients with newly diagnosed
colorectal cancer, immediate genetic testingwas found to be acceptable
[38], without causing high levels of psychological distress [39]. Since the
interval between immunohistochemistry and referral is short, it is pos-
sible that uptakewould increase if counselling is also offered later in fol-
low up. Since in our study the time frame between implementation and
evaluation of the national guideline is rather short it is possible that
some patients, who initially refused genetic counselling, are more re-
sponsive at a later stage. It might be advisable to discuss the topic
again in patients follow-up.
The strengths of our study are that we collected data from 14 hospi-
tals that collaboratewithin the two cancer networks in the Southwest of
the Netherlands and secondly that the central PALGA pathology data-
base covers almost 100% of all diagnoses resulting in a quite large co-
hort. Though we didn't have a central pathology review, all associated
laboratories perform quality controls concerning their immunohisto-
chemistry analysis. Also the objective of our study was to evaluate the
implementation of the guideline in daily practice and not the accuracy
of the pathology testing. A weakness of our study is that we have no in-
formation on the patients previous or family history (i.e., whether pa-
tients had other LS-related cancers) nor on somatic events in the two
tumours with aberrant immunohistochemistry, but no pathogenic
germline variant. Another pitfall could be that the interval between im-
plementation of the guideline (January 2016) and the opening of the co-
hort (July 2016) might be too short. Still, up till now in only a few
participating clinics a quality assuring protocol has been implemented,
therefore it is not certain that the guideline adherence improved.
There is also a potential source of bias due to the fact that we had no ac-
cess to the clinical files of patients because communication with the
gynaecologists and pathologists was done via the PALGA portal, which
ensured anonymity of all patients. Due to this we were also unable to
cross check genetic outcomes of those patients who underwent
germline testing.
5. Conclusion
The implementation of the guideline regarding LSS in endometrial
cancer has been quite successful though referral to a clinical geneticist
could be improved. The use of a standardized national synoptic pathol-
ogy report that includes results of LS immunohistochemistry should en-
sure that all patients will be screened. Local protocols should be
implemented to confirm that all patients underwent tumour screening
for LS.
The rate of referral to a clinical geneticist should be improved, in
viewof the implications for the patient and her relatives. Gynaecologists
ought to be aware of the benefits and drawbacks of knowingmutational
status, and require training in discussing this with their patients. The
mutational status is not only important for further health risks of the pa-
tient and their relatives, but may also provide possibilities for new adju-
vant treatment options, such as immune checkpoint inhibitors, PD-L1,
PD-1 in advanced or recurrent disease [40]. As demonstrated in our sur-
vey there is a knowledge gap concerning the indication for LSS causing
unawareness under gynaecologists.We advocatemore emphasis for the
need of LSS in current guidelines. Also the development of an e-learning
concerning LSS and indications for referral could be considered to im-
prove awareness.
5.1. Future implications
To prevent any barriers for usage of genetic counselling, we propose
that LSS should be performed in a uniformmanner, and that this should
be established in local protocols. This will clarify onwhich specimen the
LSS is to be performed so that gynaecologists knowwhen to expect and5
discuss the result with the patient. The local protocol should also ensure
standard quality controls within the departments involved (pathology,
gynaecology, clinical genetics) to check that all patients underwent
LSS and appropriate counselling. Those patients declining genetic
counselling should be identified, and discussion of the topic for a second
time at a later date should be considered. In our regionwe started to de-
sign such local protocols, for each participating clinic, with a (local)
quality cycle. This will enable us not only to determinewhether the im-
plementation of the guideline over time improved, but alsowhat factors
are at stake to raise the uptake to (almost) 100%.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2020.12.028.
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